 |
|
Postmenopausal Hormone Use and Symptoms of Gastroesophageal Reflux
Brian C. Jacobson, MD, MPH;
Beverly Moy, MD, MPH;
Graham A. Colditz, MD, DrPH;
Charles S. Fuchs, MD, MPH
Arch Intern Med. 2008;168(16):1798-1804.
Background Previous studies suggest that elevated levels of estrogen and progesterone, either through endogenous or exogenous sources, increase gastroesophageal reflux.
Methods To evaluate the relationship between symptoms of gastroesophageal reflux disease (GERD) and postmenopausal hormone (PMH) therapy, including the use of selective estrogen receptor modulators and over-the-counter (OTC) hormone preparations, we performed a prospective cohort study of 51 637 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of PMH therapy biennially since 1976, and information about symptoms of GERD in 2002.
Results Among eligible participants, 12 018 women (23%) reported GERD symptoms. Compared with women who never used PMHs, the multivariate odds ratio (OR) for the risk of GERD symptoms was 1.46 (95% confidence interval [CI], 1.36-1.56) for past hormone users, 1.66 (95% CI, 1.54-1.79) for current users of estrogen only, and 1.41 (95% CI, 1.29-1.54) for current users of combined estrogen and progesterone. The risk of GERD symptoms increased significantly with increasing estrogen dosage (P < .001) and increasing duration of estrogen use (P < .001). Moreover, current selective estrogen receptor modulator users experienced an OR of 1.39 (95% CI, 1.22-1.59) for GERD symptoms, and women currently using OTC hormone preparations had an OR of 1.37 (95% CI, 1.16-1.62).
Conclusions Postmenopausal use of estrogens, selective estrogen receptor modulators, or OTC hormone preparations is associated with a greater likelihood of symptoms of GERD. This suggests a hormonal component to the pathophysiologic characteristics of GERD in women.
Author Affiliations: Section of Gastroenterology, Boston Medical Center, and School of Medicine, Boston University (Dr Jacobson), Massachusetts General Hospital Cancer Center (Dr Moy), Harvard Medical School (Drs Moy and Fuchs), Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Department of Medical Oncology, Dana-Farber Cancer Institute (Dr Fuchs), Boston, Massachusetts; and Department of Surgery, School of Medicine, Washington University, St Louis, Missouri (Dr Colditz).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(16):1730.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effect of Sex on Symptoms Associated With Gastroesophageal Reflux
Chen et al.
Arch Surg 2011;146:1164-1169.
ABSTRACT
| FULL TEXT
Menopausal Hormone Therapy Use and Risk of Invasive Colon Cancer: The California Teachers Study
DeLellis Henderson et al.
Am J Epidemiol 2010;171:415-425.
ABSTRACT
| FULL TEXT
Body mass index and Barrett's oesophagus in women
Jacobson et al.
Gut 2009;58:1460-1466.
ABSTRACT
| FULL TEXT
17{beta}-Estradiol restores excitability of a sexually dimorphic subset of myelinated vagal afferents in ovariectomized rats
Qiao et al.
Am. J. Physiol. Cell Physiol. 2009;297:C654-C664.
ABSTRACT
| FULL TEXT
Heartburn from Estrogen?
JWatch Women's Health 2008;2008:2-2.
FULL TEXT
How Much Does Hormone Use Increase Risk for GERD?
JWatch Gastroenterology 2008;2008:1-1.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;337:a1661-a1661.
FULL TEXT
|
